Shanghai JiaoTong University

www.sjtu.edu.cn/
Shanghai, China

Shanghai Jiao Tong University , also referred to as SJTU, Shanghai Jiaotong University or simply Jiaotong University, is a public research university located in Shanghai, China. Established in 1896 by an imperial edict issued by the Guangxu Emperor, the university is renowned as one of the oldest and most prestigious and selective universities in China. SJTU is a member of China's C9 League and Yangtze Delta Universities Alliance.The university also annually produces the Academic Ranking of World Universities. Wikipedia.


Time filter

Source Type

The invention provides novel amphiphilic drug-drug conjugates useful as cancer therapeutics, and compositions and methods thereof.


Patent
Shanghai JiaoTong University | Date: 2014-10-31

A cooling device with small structured rib-dimple hybrid structures, comprising a substrate, a cooling channel, a plurality of small structured ribs and a plurality of dimples. The cooling channel, the plurality of small structured ribs and the plurality of dimples are all disposed on the wall surface of the substrate; the plurality of dimples are in a staggered arrangement or in a longitudinal arrangement, forming a dimple array; an upstream wall surface of each dimple or a plurality of dimples is provided with the small structured ribs, thus forming an small structured rib-dimple hybrid structure.


Ma J.,Shanghai JiaoTong University
Nature Genetics | Year: 2017

Systemic lupus erythematosus (SLE) is a heterogeneous autoimmune disease with a strong genetic component characterized by autoantibody production and a type I interferon signature. Here we report a missense variant (g.74779296G>A; p.Arg90His) in NCF1, encoding the p47phox subunit of the phagocyte NADPH oxidase (NOX2), as the putative underlying causal variant that drives a strong SLE-associated signal detected by the Immunochip in the GTF2IRD1–GTF2I region at 7q11.23 with a complex genomic structure. We show that the p.Arg90His substitution, which is reported to cause reduced reactive oxygen species (ROS) production, predisposes to SLE (odds ratio (OR) = 3.47 in Asians (Pmeta = 3.1 × 10-104), OR = 2.61 in European Americans, OR = 2.02 in African Americans) and other autoimmune diseases, including primary Sjögren's syndrome (OR = 2.45 in Chinese, OR = 2.35 in European Americans) and rheumatoid arthritis (OR = 1.65 in Koreans). Additionally, decreased and increased copy numbers of NCF1 predispose to and protect against SLE, respectively. Our data highlight the pathogenic role of reduced NOX2-derived ROS levels in autoimmune diseases. © 2017 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.


Patent
BOE Technology Group and Shanghai JiaoTong University | Date: 2015-11-05

This invention provides a thin film transistor and a manufacturing method thereof, an array substrate, and a display apparatus. This thin film transistor comprises an organic semiconductor layer and a source drain electrode layer, and further comprises a metal oxide insulating layer, wherein the metal oxide insulating layer is provided between the organic semiconductor layer and the source drain electrode layer and has a work function higher than that of the source drain electrode layer. In the thin film transistor provided by this invention, the metal oxide insulating layer having a higher work function can generate an interface dipole barrier so as to reduce the difficulty for the carriers in the source drain electrode to enter the organic semiconductor layer and thereby it is possible to decrease the contact resistance between the source drain electrode layer and the semiconductor layer and improve electrical properties of the thin film transistor.


Provided are uses of Bacteroides in preparation of a medicament. The medicament is for use in treatment or prevention of obesity and obesity-related diseases. Also provided are a pharmaceutical composition, a medicament, a food product, and an animal feed that comprise Bacteroides, uses thereof in treatment or prevention of obesity and obesity-related diseases, and a method for treatment or prevention of obesity and obesity-related diseases.


Patent
Shanghai JiaoTong University | Date: 2017-04-12

The present invention relates to the preparation methods and applications of biodegradable zinc-copper alloys, which can be applied to medical implant materials. The alloy of present invention is mainly composed of copper (1-10 wt. %), the balance of zinc and trace impurity elements. As-cast alloy ingot is homogenized and then hot processed to refine microstructure. The mechanical properties of the alloys are improved due to the refined microstructure. The alloys are capable of being further fabricated into micro-tubes, wires and plates. There are many advantages of these Zn alloys such as excellent mechanical properties, easy to process, appropriate corrosion resistance, good biocompatibility and so on, which correspondingly can be applied to many kinds of biodegradable medical implant devices. With excellent mechanical properties, good biocompatibility and degrading completely in 6-18 months, the Zn alloys meet the requirements of implant materials for mechanical properties and biosafety.


A photosensitive resin composition, comprising a binder polymer, a photopolymerizable compound, and a photopolymerization initiator, wherein the photopolymerization initiator contains a compound represented by the following general formula (1): [In the formula (1), R^(1), R^(2), R^(3 )and R^(4 )each independently represent an alkyl group, an aryl group, an aralkyl group, OR^(5), COOR^(6 )or OCOR^(7); and R^(5), R^(6 )and R^(7 )each independently represent an alkyl group, an aryl group or an aralkyl group.]


Grant
Agency: European Commission | Branch: H2020 | Program: RIA | Phase: SFS-13-2015 | Award Amount: 6.43M | Year: 2016

MycoKey aims to generate innovative and integrated solutions that will support stakeholders in effective and sustainable mycotoxin management along food and feed chains. The project will contribute to reduce mycotoxin contamination mainly in Europe and China, where frequent and severe mycotoxin contaminations occur in crops, and where international trade of commodities and contaminated batches are increasing. MycoKey will address the major affected crops maize, wheat and barley, their associated toxigenic fungi and related mycotoxins (aflatoxins, deoxynivalenol, zearalenone, ochratoxin A, fumonisins). The project will integrate key information and practical solutions for mycotoxin management into a smart ICT tool (MycoKey App), providing answers to stakeholders, who require rapid, customized forecasting, descriptive information on contamination risk/levels, decision support and practical economically-sound suggestions for intervention. Tools and methodologies will be strategically targeted for cost-effective application in the field and during storage, processing and transportation. Alternative and safe ways to use contaminated batches will be also delivered. The focus of Mycokey will be: i) innovating communications of mycotoxin management by applying ICT, providing input for legislation, enhancing knowledge and networks; ii) selecting and improving a range of tools for mycotoxin monitoring; iii) assessing the use of reliable solutions, sustainable compounds/green technologies in prevention, intervention and remediation. The multi-disciplinary consortium, composed by scientific, industrial and association partners (32), includes 11 Chinese institutions and will conduct the 4 years programme in a framework of international networks.


Grant
Agency: European Commission | Branch: H2020 | Program: RIA | Phase: INT-04-2015 | Award Amount: 3.72M | Year: 2016

This Project aims to address an increasingly pressing global challenge: How to achieve the EUs development goals and the UNs Sustainable Development Goals, while meeting the global target of staying within two degrees global warming and avoid transgressing other planetary boundaries. EU policies must align with sustainable development goals (Article 11 TFEU). The impacts of climate change and global loss of natural habitat undermine the progress achieved by pursuing the Millennium Development Goals and threaten the realisation of EU development policy goals. Our focus is the role of EUs public and private market actors. They have a high level of interaction with actors in emerging and developing economies, and are therefore crucial to achieving the EUs development goals. However, science does not yet cater for insights in how the regulatory environment influences their decision-making, nor in how we can stimulate them to make development-friendly, environmentally and socially sustainable decisions. Comprehensive, ground-breaking research is necessary into the regulatory complexity in which EU private and public market actors operate, in particular concerning their interactions with private and public actors in developing countries. Our Consortium, leading experts in law, economics, and applied environmental and social science, is able to analyse this regulatory complexity in a transdisciplinary and comprehensive perspective, both on an overarching level and in depth, in the form of specific product life-cycles: ready-made garments and mobile phones. We bring significant new evidence-based insights into the factors that enable or hinder coherence in EU development policy; we will advance the understanding of how development concerns can be successfully integrated in non-development policies and regulations concerning market actors; and we provide tools for improved PCD impact assessment as well as for better corporate sustainability assessment.


Greater bisphenol A exposure has been shown to be associated with a higher risk for self-reported adverse health outcomes, including diabetes. To examine the association between bisphenol A exposure and type 2 diabetes in adults. Cross-sectional study. Songnan, Baoshan District, Shanghai, China. 3423 local residents aged 40 years or older who were enrolled from 27 June 2008 to 10 August 2009. Urinary concentrations of bisphenol A from morning spot urine samples (exposure) and fasting plasma glucose concentration, plasma glucose concentration 2 hours after an oral glucose tolerance test, and serum insulin concentration (outcomes). Median age of the participants was 59.0 years (interquartile range, 53.0 to 68.7 years), 40% were men, and 1087 had type 2 diabetes. The median urinary bisphenol A level was 0.81 ng/mL (interquartile range, 0.47 to 1.43 ng/mL). Clinical characteristics differed between participants with normal glucose regulation and those with impaired glucose regulation and by bisphenol A quartile, but in multivariable analyses, there was no clear association between bisphenol A levels and type 2 diabetes. The adjusted odds ratio (OR) of type 2 diabetes was slightly increased for participants in the second bisphenol A quartile (0.48 to 0.81 ng/mL) (adjusted OR, 1.30 [95% CI, 1.03 to 1.64]) and the fourth quartile (>1.43 ng/mL) (adjusted OR, 1.37 [CI, 1.08 to 1.74]) but not the third quartile (0.82 to 1.43 ng/mL) (adjusted OR, 1.09 [CI, 0.86 to 1.39]), and a test of the trend of the association was not statistically significant. The cross-sectional study design and nonrandom sample of participants limit the conclusions that can be drawn. Many patients in the study already had diabetes, successful treatment of which could have obscured apparent associations. Dietary variables were not measured; however, this is necessary in observational studies of bisphenol A and diabetes because the presence of the chemical in the body may reflect consumption of sugared drinks in plastic bottles. These findings do not confirm a previously reported association between urinary bisphenol A levels and self-reported type 2 diabetes.

Loading Shanghai JiaoTong University collaborators
Loading Shanghai JiaoTong University collaborators